Clinical Trial Detail

NCT ID NCT03294694
Title Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

peritoneum cancer

Her2-receptor negative breast cancer

ovarian cancer

fallopian tube cancer

Therapies

Fulvestrant + PDR001 + Ribociclib

PDR001 + Ribociclib

Age Groups: senior adult

Additional content available in CKB BOOST